Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions rather than financial performance results.
Material Changes
On October 12, 2010, administrators notified the company of an increase in interests in Ordinary share ADRs for specific individuals. This increase resulted from the re-investment of dividends paid to shareholders on October 7, 2010. The transaction price was $41.19 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: October 12, 2010.
- Transaction Type: Re-investment of dividends into Ordinary share ADRs.
- Price per ADR: $41.19.
- Notified Individuals: Mrs C E Bruck Slaoui (3.52 ADRs) and Mr D J Phelan (208.00 ADRs).
- Dividend Payment Date: October 7, 2010.